Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2015, Issue 4


Domínguez-Borgúa A, González I, Morales L, Martínez-Carrillo FM, Palacios P
Toxic epidermal necrolysis and development of liver abscesses
Gac Med Mex 2015; 151 (4)

Language: Español
References: 26
Page: 512-518
PDF: 265.28 Kb.


Full text




ABSTRACT

Pharmacologic hypersensitivities commonly express cutaneous manifestations, and the highest mortality is found in Stevens Johnson’s syndrome and toxic epidermal necrolysis, mostly associated with antibiotics and anticonvulsive drugs. Toxic epidermal necrolysis is related in 80% of cases to pharmacologic hypersensitivity and systemic consequences may be found; hepatic injury has been described, but the finding of liver abscesses has not been reported among common injuries. The case of a patient with a rapid development of multiple liver abscesses in the clinical setting of hypersensitivity due to lamotrigine and the discussion of probable etiologies and management is presented.


Key words: Toxic epidermal necrolysis, Drug hypersensitivity, Liver abscess, Intravenous immunoglobulin.


REFERENCIAS

  1. French LE. Toxic epidermal necrolysis and Steven Jonhnson syndrome: our current understanding. Allergol Int. 2006;55(1):9-16.

  2. Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res. 2008;29(5):706-12.

  3. Jean-Claude I, García DR. Necrólisis epidémica tóxica y síndrome de Stevens-Johnson: clasificación y actualidad terapéutica. Actas Dermosifiliogr. 2000;91:541-51.

  4. Serati Shirazi Z, Inaloo S. Intravenous immunoglobulin in the treatment of lamotrigine- induced toxic epidermal necrolysis. Iran J Allergy Asthma Immunol. 2008;7(4):239-41.

  5. Heneghan HM, Healy NA, Martin ST, et al. Modern management of pyogenic hepatic abscess: a case series and review of the literature. BMC Res Notes. 2011;4:80.

  6. Krige JE, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system. BMJ. 2001;322(7285):537-40.

  7. Widgerow AD. Toxic epidermal necrolysis - management issues and treatment options. Int J Burns Trauma. 2011;1(1):42-50.

  8. Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995-1003.

  9. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187.e1-16; quiz 203-4.

  10. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173.e1-13; quiz 185-6.

  11. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis. Br J Dermatol. 2012;167(2):424-32.

  12. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141(6):683-7.

  13. Castelain F, Humbert P. Toxic epidermal necrolysis Curr Drug Saf. 2012;7(5):332-8.

  14. Meddings L, Myers RP, Hubbard J, et al. A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol. 2010;105(1):117-24.

  15. Molgó M, Carreño N, Hoyos-Bachiloglu R, Andresen M, González S. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases]. Rev Med Chil. 2009;137(3):383-9.

  16. Laguna C, Martín B, Torrijos A, García-Melgares ML, Febrer I. Stevens- Johnson syndrome and toxic epidermal necrolysis. Actas Dermosifiliogr. 2006;97(3):177-85.

  17. Prins C, Kedel FA, Padilla S, Et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003 Jan; 139(1):26-32.

  18. Foster R, Suri A, Filate W, et al. Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfus Med. 2010;20(6):403-8.

  19. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 2008;74(3):238-40.

  20. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.

  21. Clements WD, Diamond T, McCrory DC, Rowlands BJ. Biliary drainage in obstructive jaundice: experimental and clinical aspects. Br J Surg. 1993;80(7):834-42.

  22. Malik AA, Bari SU, Rouf KA, Wani KA. Pyogenic liver abscess: Changing patterns in approach. World J Gastrointest Surg. 2010;2(12):395-401.

  23. Huang CJ, Pitt HA, Lipsett PA, et al. Pyogenic hepatic abscess. Changing trends over 42 years. Ann Surg. 1996;223(5):600-7; discussion 607-9.

  24. Chung YF, Tan YM, Lui HF, et al. Management of pyogenic liver abscesses - percutaneous or open drainage? Singapore Med J. 2007;48(12):1158-65.

  25. Hope WW, Vrochides DV, Newcomb WL, Mayo-Smith WW, Iannitti DA. Optimal treatment of hepatic abscess. Am Surg. 2008;74(2):178-82.

  26. Malik AA, Bari SU, Rouf KA, Wani KA. Pyogenic liver abscess: Changing patterns in approach. World J Gastrointest Surg 2010;2(12): 395-401.






>Journals >Gaceta Médica de México >Year 2015, Issue 4
 

· Journal Index 
· Links 






       
Copyright 2019